logo-loader
RNS
viewAvacta Group PLC

Moderna Exercises Exclusive Product License Option

/**/ sup{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ad{size:595.0pt 842.0pt;margin:63.8pt 72.0pt 2.0cm 72.0pt;}div.ad{}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm; text-align: center}span.br{font-size:11.0pt;font-family: "Calibri","sans-serif"}p.bu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm}span.bp{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; text-align: right}p.bx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; text-align: center}p.by{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph} span.bk{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.bj{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph}span.bh{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph}span.bf{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}table.cb{width:460.4pt;margin-left:-5.1pt;border-collapse:collapse}tr.ay{height:43.9pt}td.bc{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:43.9pt}span.bd{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black} td.az{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:43.9pt}span.bb{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ba{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}tr.ar{height:99.2pt}td.aw{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:99.2pt}p.cc{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:115%}td.as{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt; height:99.2pt}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";margin-bottom: 0cm; text-align: justify; text-decoration: underline; text-justify: inter-ideograph}span.ce{font-family:"Times New Roman","serif";color:blue;text-decoration:underline;color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: none}span.at{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black} td.aq{width:245.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.ao{width:193.8pt;padding:0cm 5.4pt 0cm 5.4pt}span.ap{font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: underline}p.cf{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; line-height: 115%; margin: 0cm; margin-bottom: .0001pt; text-align: justify; text-justify: inter-ideograph}span.am{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif";color:black}p.cg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%}span.ak{font-size:11.0pt;line-height:115%;font-family: "Calibri","sans-serif";color:black}p.ch{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph;line-height:115%}span.ci{font-family:"Times New Roman","serif";font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}span.ai{font-size:11.0pt;line-height: 115%;font-family:"Calibri","sans-serif";color:black} span.ah{font-size:11.0pt; line-height:115%;font-family:"Calibri","sans-serif"}span.ag{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.cj{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Cambria","serif";font-div: italic; line-height: 115%; margin-bottom: 0cm; text-align: justify; text-justify: inter-ideograph}span.af{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black;background:white} /**/
RNS Number : 9010O
Avacta Group PLC
04 February 2019
 

 

 

 

 

 

4 February 2019

 

Avacta Group plc

 

("Avacta", the "Group" or the "Company")

 

Moderna Exercises Option for an Exclusive Product License

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.

 

In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta's Affimer technology for certain collaboration targets and the option to enter into exclusive license agreements on pre-agreed terms to further research, develop and commercialize Affimers selected by Moderna.

 

Under the terms of the agreement Avacta may receive undisclosed payments upon future clinical development milestones and royalties in connection with future product sales.

 

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:

"I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to certain Affimer molecules that have been generated through our collaboration. This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development.

 

We will continue to support Moderna and their development objectives and I look forward to updating the market as and when key development milestones are met."

 

-Ends -

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

finnCap Ltd

Geoff Nash / Giles Rolls - Nominated Adviser

Tim Redfern - ECM

 

WG Partners

Nigel Birks / Nigel Barnes

David Wilson / Claes Spang

 

 

 

Tel:  +44 (0) 207 220 0500

www.finncap.com

 

 

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Turner Pope Investments

James Pope

Ben Turner

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

 

Yellow Jersey (Financial Media and IR)

Sarah Hollins

Harriet Jackson

Tel: 020 3621 4120

www.turnerpope.com

 

 

Tel: +44 (0)7787 502 947

[email protected] 

 

 

Tel: +44 (0)7764 947137

Tel: +44 (0)7544 275882

[email protected]

 

 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability.  Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBRGDDIGGBGCB

Quick facts: Avacta Group PLC

Price: 18.25

Market: AIM
Market Cap: £21.2 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19